DMTX Dimension Therapeutics Inc

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimension Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Rowley Law PLLC is investigating potential claims against Dimension Therapeutics, Inc. (NASDAQ: DMTX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by REGENXBIO Inc. in an all-stock transaction valued at approximately $85.4 million. The transaction is expected to close by the end of 2017.

If you are a Dimension Therapeutics, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/dimension. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).  

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com. 

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
25/08/2017

Underlying

DMTXDimension Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dimension Therapeutics Inc

 PRESS RELEASE
Free
DMTX Dimension Thera...

INVESTOR ALERT: Brower Piven Commences an Investigation into the Propo...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Dimension Therapeutics, Inc. (Nasdaq: DMTX) (“Dimension Therapeutics” or the “Company”) relating to the proposed buyout of Dimension Therapeutics by REGENXBIO Inc. Under the terms of the agreement, Dimension Therapeutics shareholders are anticipated to receive 0.1573 shares of REGE...

August 31, 2017 1 EN
 PRESS RELEASE
Free
DMTX Dimension Thera...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Dimens...

NEW YORK--(BUSINESS WIRE)-- Rowley Law PLLC is investigating potential claims against Dimension Therapeutics, Inc. (NASDAQ: DMTX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by REGENXBIO Inc. in an all-stock transaction valued at approximately $85.4 million. The transaction is expected to close by the end of 2017. If you are a Dimension Therapeutics, Inc. shareholder and are interested in obtaining additional information regarding this investigation, please ...

August 25, 2017 1 EN
 PRESS RELEASE
Free
DMTX Dimension Thera...

SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Pr...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Dimension Therapeutics, Inc. (Nasdaq: DMTX) (“Dimension Therapeutics” or the “Company”) relating to the proposed buyout of Dimension Therapeutics by REGENXBIO Inc. Under the terms of the agreement, Dimension Therapeutics shareholders are anticipated to receive 0.1573 shares of REGE...

August 25, 2017 1 EN
 PRESS RELEASE
Free
DMTX Dimension Thera...

DIMENSION THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A....

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Dimension Therapeutics, Inc. (NASDAQ GS: DMTX)? Did you purchase any of your shares prior to August 25, 2017? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Dimension Therapeutics, Inc. (“Dimension” or the “Company”) (NASDAQ GS...

August 25, 2017 1 EN
 PRESS RELEASE
Free
DMTX Dimension Thera...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Dimension Therapeutics, Inc. (“Dimension Therapeutics” or the “Company”) (NASDAQ:DMTX) stock prior to August 25, 2017. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Dimension Therapeutics to REGENXBIO Inc. (NASDAQ:RGNX) for 0.1573 shares of REGENXBIO per Dimension Therapeutics share. Based on the closing pric...

August 25, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch